NCT05234307 - PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

Interventions

DRUG

Adenosine A2B Receptor Antagonist PBF-1129

Given PO

PROCEDURE

Biospecimen Collection

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Dwight Owen

OTHER